The effectiveness of combination antiretroviral therapy (cART) continues to improve as treatment choices expand with the development of new antiretroviral agents and regimens. However, the successful long-term treatment of HIV/AIDS is under threat from the emergence of drug-resistant strains to multiple agents and entire drug classes.
Introduction
Long-term management of HIV/AIDS is at risk of increasing drug resistance (1) . Booster protease inhibitor (PI) and thymidine analogue-containing regimens have a high genetic barrier to resistance (25). Non-thymidine-analogue triple nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination regimens and Non-nucleoside reverse transcriptase inhibitors on the contrary have a low genetic barrier to resistance (6) (7) (8) (9) . Unfortunately, several low genetic barrier agents select for mutations that confer broad class resistance (10, 11) . The selection of the K103N and Y181C mutations cause loss of activity to all currently available NNRTIs. Most NRTIs are rendered inactive by the selection of the K65R mutation (12) . The M184V mutation in addition causes loss of activity to both lamivudine (3TC) and emicitrabine (FTC), but has been shown to confer viral resensitisation to zidovudine (ZDV), stavudine (d4T) and tenofovir (TDF) (12) and delay in thymidine analogue mutations (TAMs) emergence (5). L74V mutation selection causes decreased antiviral activity of abacavir (ABC), didanosine (ddI), and zalcitabine (ddC), and when the mutated virus is selecting for both L74V and M184V, only the thymidine analogues (ZDV and d4T) and TDF retain susceptibility (12) . In this paper, we review literature focusing on the genetic barrier to resistance as the basis of selection of first and second line antiretroviral therapy. 
Results
Based on the search terms, the searches yielded 185 articles eligible for inclusion. After titles and abstracts were reviewed, only 22 articles were reviewed in full, of which 9 presented data sufficient for inclusion in the final analysis.
Discussion
With growing access to CART in low-resource settings, treatment options in terms of better and less toxic medications is also increasing. Table I shows different literature discussing genetic barriers of various commonly used cART with their corresponding virologic suppression rate. The decision to use low or high genetic antiretroviral regimens as initial cART in treatment naïve patients is not definitive and is largely governed by availability especially in resource-limited settings. Booster PI-based regimens generally have a high genetic barrier to resistance (1, 13, 15, 16, (18) (19) (20) and are recommended for use but gastrointestinal adverse drug effects precludes their use as first line therapy and is mainly reserved for second line therapy21. Selection of low genetic barrier combinations on the contrary, may result into broad class resistance hence reducing treatment options10, 11. Genetic barrierinformation however, may provide guidance to health workers on the selection of optimal cART regimens to improve the durability of CART and therefore ensure treatment success. Combinations of both low and high genetic barrier ART drugs are recommended. These combinations of high and low genetic barrier ART may produce potent first-line therapy. The ramification of potent cART is effective virologic control which is not easily rendered inactive in cases of poor adherence.
Conclusion
Different regimens have different genetic barriers to resistance and the recommendation would be to use combinations of low and high genetic barrier drugs for instance ZDV in combination with low genetic barrier drugs as first-line therapy. Use of low genetic barrier regimens as first line therapy confers broad class resistance over more than one group of ARVs. Use of high genetic barrier regimens as first line therapy on the contrary, requires a number of mutations to be rendered inactive and therefore will allow clinicians to be able to provide both support and adherence counselling so as to ensure treatment success for subsequent regimens.
